Hematopoiesis News Volume 3.41 | Oct 16 2012

    0
    27

    Hematopoiesis News 3.41 October 16, 2012
    Hematopoiesis News
         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Hematopoiesis News on Twitter

    TOP STORY
    HLA-Mismatched Stem-Cell Microtransplantation as Postremission Therapy for Acute Myeloid Leukemia: Long-Term Follow-Up
    One hundred one patients with acute myeloid leukemia in first complete remission from four treatment centers received programmed infusions of G-CSF-mobilized HLA-mismatched donor peripheral-blood stem cells after each of three cycles of high-dose cytarabine conditioning without graft-versus-host disease prophylaxis. [J Clin Oncol] Abstract

    LIVE Webinar: Faster 7-Day CFU Assays for the Enumeration of Hematopoietic Progenitor Cells in CB. Register now!

    PUBLICATIONS (Ranked by impact factor of the journal)

    LABORATORY RESEARCH

    Perturbation of Fetal Liver Hematopoietic Stem and Progenitor Cell Development by Trisomy 21
    Scientists showed that primary trisomy 21 fetal liver hematopoietic stem cells and megakaryocyte-erythroid progenitors are markedly increased, whereas granulocyte-macrophage progenitors are reduced. [Proc Natl Acad Sci USA] Full Article

    BCR-ABL1 Kinase Inhibits Uracil DNA Glycosylase UNG2 to Enhance Oxidative DNA Damage and Stimulate Genomic Instability
    Researchers report that chronic myeloid leukemia in chronic phase leukemia stem and progenitor cell populations accumulate high amounts of reactive oxygen species, which may result in accumulation of uracil derivatives in genomic DNA. [Leukemia] Abstract

    CD34+/CD38- Acute Myelogenous Leukemia Cells Aberrantly Express CD82 which Regulates Adhesion and Survival of Leukemia Stem Cells
    To identify molecular targets in leukemia stem cells, investigators compared the protein expression profile of freshly isolated CD34+/CD38 cells with that of CD34+/CD38+ counterparts from individuals with acute myelogenous leukemia using isobaric tags for relative and absolute quantitation. [Int J Cancer] Abstract

    Aging Induced Decline in T-Lymphopoiesis Is Primarily Dependent on Status of Progenitor Niches in the Bone Marrow and Thymus
    By grafting young wild-type (WT) bone marrow (BM) progenitors into aged IL-7R-/- hosts, which possess WT-equivalent niches although lympho-hematopoietic progenitor/stem cells are defect, investigators demonstrated that these young BM progenitors exhibited a myeloid skew. [Aging] Full Article

    Successful Isolation and Expansion of CMV-Reactive T Cells from G-CSF Mobilized Donors that Retain a Strong Cytotoxic Effector Function
    Scientists investigated the use of a small aliquot of a granulocyte-colony stimulating factor (G-CSF) mobilized hematopoietic stem cell transplantation graft to manufacture cytomegalovirus (CMV)-specific T cells. [Br J Haematol] Abstract

    Expression and Function of PML-RARA in the Hematopoietic Progenitor Cells of Ctsg-PML-RARA Mice
    Scientists showed that both Ctsg, and PML-RARA targeted to the Ctsg locus (in Ctsg-PML-RARA mice), are expressed in the purified Kit+LinSca+ cells of these mice and this expression results in biological effects in multi-lineage competitive repopulation assays. [PLoS One] Full Article

    Impact of Different Dimethyl Sulphoxide Concentrations on Cell Recovery, Viability and Clonogenic Potential of Cryopreserved Peripheral Blood Hematopoietic Stem and Progenitor Cells
    Researchers tested if dimethyl sulphoxide concentration might be reduced without negative impact on cell recovery and clonogenicity of autologous hematopoietic stem/progenitor cells. [Vox Sang] Abstract

    CLINICAL RESEARCH

    Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Mildly Reduced Renal Function Based on Creatinine Clearance before Transplantation
    Researchers retrospectively assessed how mildly reduced renal function as defined based on creatinine clearance rate affects renal comorbidity after allogeneic hematopoietic stem cell transplantation. [Ann Hematol] Abstract

    Predictors of Hemoglobin Response to Eculizumab Therapy in Paroxysmal Nocturnal Hemoglobinuria
    Thirty patients with paroxysmal nocturnal hemoglobinuria clones were treated with eculizumab and classified as complete responders (4 patients), good partial responders (16) and suboptimal responders (10) over 863 patient-months of treatment. [Eur J Haematol] Abstract

    FREE Technical Resource: Atlas of Hematopoietic Colonies from Cord Blood. Request your copy.

    REVIEWS
    Induction of Antigen-Specific Tolerance through Hematopoietic Stem Cell-Mediated Gene Therapy: The Future for Therapy of Autoimmune Disease?
    Focusing on T-cell mediated autoimmune diseases, the authors reviewed progress made in antigen-specific immunotherapy using hematopoietic stem cell transplantation (HSCT)-mediated approaches, induction of tolerance in effector and memory T cells and the challenges for progression and clinical application of antigen-specific ‘tolerogenic’ HSCT therapy. [Autoimmun Rev] Abstract

    INDUSTRY NEWS

    The Terry Fox Foundation Provides $13.4 million for Research into Fighting Cancer with Viruses and Finding Ways to Treat Acute Leukemias
    Fundings from the Terry Fox Foundation will support an Ottawa, Ontario-based team conducting research into oncolytic viruses to treat various forms of cancer and a Vancouver, British Columbia-based team exploring why acute forms of leukemia are difficult to treat. [The Terry Fox Foundation] Press Release

    Sanofi and Massachusetts General Hospital Launch Oncology Research Collaboration
    Sanofi announced a two-year agreement with Massachusetts General Hospital aimed at furthering translational medicine research to develop new treatments for various types of hematological malignancies and solid tumors. [Sanofi Oncology] Press Release

    Pharmacyclics® Triggers another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial
    Pharmacyclics, Inc. announced that the international, randomized phase III clinical trial of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a third $50 million milestone payment obligation from Janssen Biotech, Inc., worldwide collaborator on ibrutinib in oncology and sponsor of this trial. [Pharmacyclics, Inc.] Press Release

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)
     
    Center for Biologics Evaluation and Research (United States)
     
    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS
    NEW Workshop on Approval and Commercialization of Advanced Therapy Medicinal Products in Europe
    November 15, 2012
    Berlin, Germany

    Visit our events page to see a complete list of events in the hematopoietic community.

    JOB OPPORTUNITIES

    Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

    Research Technologist – Media Development (STEMCELL Technologies, Inc.)

    Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

    Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

    Scientific Communications and Publishing Coordinator (STEMCELL Technologies, Inc.)

    Product Quality Scientist (STEMCELL Technologies, Inc.)

    Research Associate – Quality Assurance (University of California)

    Postdoctoral Position – Mouse Stem Cell Biology (University of Alabama)

    Postdoctoral Position – Stem Cells and Cancer (Tsinghua University)

    Scientist, Postdoctoral and Research Associate Positions (University of Miami – Sylvester Comprehensive Cancer Center)

    Postdoctoral Position – Impact of Inflammation on Hematopoiesis and Cancer (University of Murcia)

    Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us